Statement on Behalf of Dr Sarah Myhill Concerning GMC Hearing of 29 April

LONDON, April 27, 2010 – Statement on behalf of Dr Sarah Myhill:

On Thursday 8th April 2010, Dr Sarah Myhill, a private GP, was summoned
to a GMC Hearing on Monday 12th April so that her license to practise
medicine could be suspended whilst anonymous allegations against her were
investigated. The GMC gave her [...]

Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol

HOERSHOLM, Denmark and SAN DIEGO, April 27, 2010 – — Santaris Pharma A/S selects lead research compound SPC5001 targeting
PCSK9 to advance into drug development for the treatment of high cholesterol

— PCSK9, an important new target, is a protein involved in regulating
LDL or "bad" cholesterol in the blood- a major risk [...]

G8 Development Ministers Must Heed Early Warning Signs of Cutbacks to AIDS Funding

DELHI, India and KAMPALA, Uganda, April 26, 2010 – Rationing Funds, Risking Lives: World Backtracks on HIV Treatment, the
new report from the International Treatment Preparedness Coalition (ITPC),
documents early warning signs resulting from the global pullback on AIDS
commitment and funding: caps on the number of people enrolled in treatment
programmes, more frequent drug stock outs, and [...]

Take the Stress Out of Everyday Life With Mikki!

Mikki are the Proud Sponsors of National Grooming Week in Conjunction With National Pet Month 24th April – 1st May 2010

LONDON, April 26, 2010 – Mikki, sponsors of National Grooming Week, recognise that the
bond between people and animals is a strong one and one which can actually
benefit any pet owner. Recent research carried out [...]

Health Robotics to Showcase CytoCare at ISOPP (May 2010) and Charles University’ General Faculty Hospital of Prague

BOZEN, Sud-Tirol, Italy, April 26, 2010 – Health Robotics today announced the upcoming cooperation with the
International Society of Oncology Pharmacy Practitioners (ISOPP), B|Braun
Melsungen, and the General Faculty Hospital of Prague to host ISOPP delegates
at its bi-annual congress to witness live demonstrations of CytoCare in an
Oncology patient setting. CytoCare is the only robot in the [...]

IMPLANET Raises Additional EUR 8 Million (USD 11 Million) to Fuel Deployment

IMPLANET Raises EUR 8 Million
BORDEAUX, France, April 26, 2010 – Thanks to promising commercial debut of its products (Surgical
implants for Orthopedic and Spine surgery) and its Healthcare Information
Technologies service offer (fully integrated and automated patient/product
tracking and supply chain) IMPLANET S.A. raises an additional EUR 8 million
(USD 11 million).

IMPLANET is proud [...]

Record Attendance Expected At UBM’s Chinese Pharma Events

AMSTERDAM, April 26, 2010 – Continued double digit growth in the Chinese pharmaceutical industry is
reflected in record visitor pre-registration levels and a sell-out of
exhibition space at this year's UBM International Media China events – CPhI,
ICSE, P-MEC and BioPh – which will run from June 2-4 at the Shanghai New
International Expo Centre.

[...]

Pro-Tect, Inc. Acquires Revolutionary Drug Delivery Patents

WEST CALDWELL, New Jersey, April 26, 2010 – Pro-Tect Pharmaceuticals, Inc. (PRTT) announced today that it has
completed the acquisition of multiple patents and patents-pending from
Nectid, Inc., that enable three revolutionary drug delivery technologies.

The acquired patents would enable Pro-Tect to provide efficient,
effective drug delivery platforms for three essential yet currently unmet
needs:

[...]

GSK Awards Celebrate Unsung Excellence in Health Care

LONDON, April 26, 2010 – Ten award-winning charities will each receive GBP25,000 in
recognition of their outstanding work in addressing some of the most
difficult health issues and improving health care in some of the UK's most
deprived communities.

The GSK IMPACT Awards, a partnership with independent health
charity The King's Fund, celebrate the vital [...]

The European Commission’s FP7 Programme to Boost the Life Science R&D Funding in Europe, Finds Frost & Sullivan

LONDON, April 27, 2010 – Europe is moving towards becoming a knowledge-based economy. Keeping in
line with this objective, the European commission has instituted the
Framework 7 (FP7) programme. Launched to support the re-launched Lisbon
strategy, FP7 focuses on research themes rather than the framework programmes
of the past. It has been designed to meet some of the [...]

MarketsandMarkets: Global OLED Market Worth US$2.2 Billion by 2014

DALLAS, Texas, April 27, 2010 – According to a new market research report, 'Opportunities in the Global
OLED Display Market', published by MarketsandMarkets
(www.marketsandmarkets.com), the global OLED product market is
expected to be worth US$2.2 billion by 2014, growing at a CAGR of 24.7% from
2009 to 2014. The Asia-Pacific market is expected to account for nearly 90%
of [...]

ASP Sterrad Technology Approved by AFSSAPS for Total Inactivation of Prions

French Health Products Safety Agency AFSSAPS Approves STERRAD(R) Hydrogen Peroxide Gas Plasma Technology for Total Inactivation of Protein-based Infectious Agents Linked to Fatal Brain Diseases

PARIS, April 27, 2010 – Advanced Sterilization Products (ASP) announced today that the French
Health Products Safety Agency, AFSSAPS, will approve the low-temperature
hydrogen peroxide gas plasma STERRAD(R) NX(TM) and the STERRAD(R) [...]

Kiadis Pharma Provides ATIR(TM) Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality

FDA Grants ATIR(TM) Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality

AMSTERDAM, April 28, 2010 – Kiadis Pharma today provided an update on its cell therapy product
ATIR(TM) developed for mismatched bone marrow transplants. ATIR(TM) continues
to show excellent clinical results in patients who received a mismatched bone
marrow transplantation from a [...]

Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen

DUBLIN, April 27, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that it has received a Paragraph IV
Notice Letter from Anchen Pharmaceuticals, Inc. ("Anchen") advising of the
filing of an Abbreviated New Drug Application ("ANDA") for a generic version
of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine [...]

Torchmark Corporation Reports First Quarter 2010 Results

MCKINNEY, Texas, April 27, 2010 – Torchmark Corporation (NYSE: TMK) reported today that for the quarter
ended March 31, 2010, net income was US$1.46 per share compared with US$0.91
per share for the year-ago quarter. Net operating income for the quarter was
US$1.52 per share, a 2% increase compared with US$1.49 per share for the
year-ago quarter.

[...]

Hand Hygiene is Driving the Infection Control Market: Frost & Sullivan Web Conference on the European Hand Hygiene Market

LONDON, April 28, 2010 – The 2009 outbreak of the H1N1 influenza virus, commonly known as the
"Swine Flu," has instigated various initiatives in the infection control
industry with major emphasis on the hand hygiene market. In response to rapid
industry growth, market participants are preparing to meet the growing demand
for infection control solutions and jockeying for [...]

Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL-C Target Attainment Over 52 Weeks

Pitavastatin Represents Effective Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia

WOKINGHAM, England, April 28, 2010 – New long-term phase III data published today in Atherosclerosis
demonstrates that, of patients with primary hypercholesterolaemia or combined
dyslipidaemia who received 4mg of pitavastatin, 74% and 73.5% achieved NCEP*
and EAS* low-density lipoprotein cholesterol (LDL-C) targets at 52 [...]

Expanding Beyond the Horizon: MarketsandMarkets Forecasting and Analytics Services to Help Pharmaceuticals Companies Tap Opportunities in Emerging Markets

DALLAS, April 28, 2010 – The pharmaceutical industry across the globe is currently facing a number
of challenges, including non-productive pipelines, stringent regulatory
pathways, threat from generic drugs, and cost containment pressure from the
governments in developed markets. However, emerging markets such as the BRIC
economies (Brazil, Russia, India, and China) offer pharma companies a
valuable opportunity as these [...]

MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014

DALLAS, Texas, April 29, 2010 – According to a new market research report, 'global oncology
biomarker market', published by MarketsandMarkets
(www.marketsandmarkets.com), The global oncology biomarker market is
expected to grow from $4.1 billion in 2009 to $9.5 billion in 2014 at a CAGR
of 18.1% from 2009 to 2014. The Global Oncology Biomarkers Market report
analyzes the oncology biomarkers [...]

Your Brain on Resveratrol

LONDON, April 29, 2010 – Can Resveratrol, the so-called miracle molecule found in red wine,
peanuts and an obnoxious plant called Chinese Giant Knotweed, actually
improve your brain function?

Scientists at Northumbria University in the UK have just published a
double-blind, peer-reviewed study in the journal, American Journal of
Clinical Nutrition, which concludes that a [...]

Shire’s Replenished Portfolio Drives Excellent Quarterly Performance

DUBLIN, April 29, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to March
31, 2010.

Financial Highlights

[...]

Dysentery: Don’t Let it Ruin Your Time Abroad

LONDON, April 29, 2010 – Dysentery

– Dysentery is a Common Problem for Expatriates Moving Abroad
– Poor Sanitation is Often the Cause
– Following a Few Simple Tips Can Avoid Serious Illness
– MediCare International (www.medicare.co.uk) Policies Cover
Dysentery Cases
[...]

European Workers Would Trade Money for an Early Retirement

A Third of European Workers Unhappy With Government Policy to Raise Retirement Age in Their Country

ROTTERDAM, The Netherlands, April 29, 2010 – The lure of retirement is simply too much for many Europeans
with almost one in three workers (29%) saying they would prefer their
government not to raise the national retirement age, and would be [...]

Gerresheimer Well-Positioned for Further Growth

D??SSELDORF, Germany, April 29, 2010 -

– Financial Year 2009 Successfully Completed

– Good Start to the Year 2010

– Confirmation of Guidance of 2% to 4% Sales Growth for 2010
With an Operating Margin of Around 19.5%

[...]

Agilisys Awarded 10 Year Contract With General Healthcare Group – The UK’s Largest Independent Healthcare Provider

Agilisys Helps General Healthcare Group Improve Patient Services and Reduce Costs With End-to-end Management of RIS-PACS Platform

LONDON, April 29, 2010 – Agilisys, the UK's most innovative IT services and outsourcing provider,
today announced that it has been awarded a 10-year contract by General
Healthcare Group, the UK's largest independent healthcare provider, to manage
their Radiology Information Systems [...]

New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy

HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 – Today, at the 11th Annual Meeting of the American Society of Breast
Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced
that Breast Cancer Research and Treatment has published an important study
demonstrating the benefit of adjuvant chemotherapy for patients with a
high-risk of breast cancer recurrence according [...]

Ingrid Klingmann Joins CRF Health as Consulting Clinical Advisor

LANSDALE, Pennsylvania, April 29, 2010 – Ingrid Klingmann, MD, PhD, FFPM, FBCPM, recently joined CRF Health as
consulting Clinical Advisor. With over 20 years of experience in the clinical
trial sector, Dr. Klingmann brings a wealth of global clinical experience to
CRF Health, the electronic patient reported outcomes (ePRO) solutions
company. In her position as Clinical Advisor, Dr. [...]

Zeltia Achieves Consolidated EBITDA Break-Even in 1Q10

Yondelis(R) sales increased by 110% with respect to 1Q09
MADRID, April 29, 2010 – Consolidated revenues for Zeltia (ZEL.MC) amounted to 32.9 million euro
in 1Q10, up 49% with respect to 1Q09. Net income improved 50%.

Net revenues in biopharmaceuticals rose 90.9%, primarily due to
Yondelis(R) sales, which totalled 16.6 million euro in the [...]

Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis

LONDON, NEW YORK and HAMILTON, Bermuda, April 30, 2010 – Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma"), the
global private equity firm focused on the biotechnology and pharmaceutical
industries, announced today the enrolment of the first patient into its Phase
III trial of TDT 067, terbinafine in Transfersomes(R), for the topical
treatment of onychomycosis (also known as a fungal [...]